In this study, we aimed to investigate the effects of androgen receptor (AR) expression, as well as the AR/ER and AR/PR ratios, on responses to CDK4/6 inhibitor treatment and progression-free survival (PFS) in breast cancer patients. Here, ESR1 is linked to breast cancer.